The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2005
DOI: 10.21236/ada443732
|View full text |Cite
|
Sign up to set email alerts
|

Identification of Breast Cancer - Specific Proteolytic Activities for Targeted Prodrug Activation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2009
2009
2009
2009

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 15 publications
(32 reference statements)
0
1
0
Order By: Relevance
“…5). In addition, PSA-activated prodrugs have been designed for treatment of prostate cancer based on the fact that serum PSA is mostly enzymatically inactive, whereas in the prostate gland, it is found in its active form (6). Notably, administration of recombinant KLK6 to mice with EAE resulted in the production of anti-KLK6 antibodies that inhibited its enzymatic activity, attenuated the severity of symptoms, and delayed the course of disease progression (7).…”
Section: The Klk Familymentioning
confidence: 99%
“…5). In addition, PSA-activated prodrugs have been designed for treatment of prostate cancer based on the fact that serum PSA is mostly enzymatically inactive, whereas in the prostate gland, it is found in its active form (6). Notably, administration of recombinant KLK6 to mice with EAE resulted in the production of anti-KLK6 antibodies that inhibited its enzymatic activity, attenuated the severity of symptoms, and delayed the course of disease progression (7).…”
Section: The Klk Familymentioning
confidence: 99%